References
- Schito GC. The importance of the development of antibiotic resistance in Staphylococcus aureus. Clin Microbiol Infect 2006; 12 (suppl 1): 3-8.
- Menichetti F. Current and emerging serious Gram-posi-tive infections. Clin Microbiol Infect 2005; 11 (suppl. 3):22-28.
- Segreti J. Efficacy of current agents used in the treat-ment of Gram-positive infections and the consequences of resistance. Clin Microbiol Infect 2005; 11 (suppl 3): 29-35.
- Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42 (12): 3251–3255.
- Patel U, Yan YP, Hobbs FW, Jr., et al. Oxazolidinones mechanism of action: inhibition of the first peptide bond for-mation. J Biol Chem 2001; 276 (40): 37199–205.
- Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004; 23 (2): 113–119.
- Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39 (7): 1010–1015.
- Kloss P, Xiong L, Shinabarger DL, Mankin AS. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294 (1): 93–101.
- Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002; 46 (10): 3334–3336.
- Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics. Antimicrob Agents Chemother 2006; 50 (7): 2500–2505.
- Mankin A, Toh S-M, Xiong L, Lolans K, Quinn JP. A new mechanism of linezolid resistance in mRSA based on posttranslational modification. In: Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; San Francisco, CA; 2006: 80.
- Komine T, Takano H, Kojima A, Asahina Y, Fukuda Y. Synthesis and SAR of Highly Potent Novel Antibacterial Oxazolidinone. Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco CA 2006: 212.
- Ebisu HAR, Takei M, Fukuda H. Novel oxazolidinones: antibacterial activities against respiratory pathogens and drug-resistant gram positive bacteria. In: Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; 2006; San Francisco, CA; 2006: 212.
- Gill CJ, Abruzzo GK, Flattery AM, et al. In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection. In: Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Societyfor Microbiology; 2006; San Francisco, CA; 2006: 212.
- Ebisu H, Abuki R, Takei M, et al. In vivo efficacey of a novel oxazolidinone compound in three pulmonary models of infection. In: Abstracts of the 46th Interscience Conference on Antimirobial Agents and Chemotherapy, American Society for Microbiology; 2006; San Francisco, CA; 2006: 212.
- Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activ-ities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40 (4): 839–845.
- Pillai SK, Sakoulas G, Wennersten C, et al. Linezolid resistance in Staphylococcus aureus: characterization and sta-bility of resistant phenotype. J Infect Dis 2002; 186 (11): 1603–1607.
- Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resis-tance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358 (9277): 207–208.
- Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and compari-son of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001; 45 (7): 2154–2156.
- Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to van-comycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357 (9263): 1179.
- Lobritz M, Hutton-Thomas R, Marshall S, Rice LB. Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis. Antimicrob Agents Chemother 2003; 47 (10): 3318–3320.
- Rahim S, Pillai SK, Gold HS, Venkataraman L, Inglima K, Press RA. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003; 36 (11): E146–148.